Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
EPILEPSY DRUG RUFINAMIDE FROM EISAI

 

Epilepsy drug rufinamide: Eisai seeks US FDA nod

 

BY OUR PHARMA CORRESPONDENT

15 September,2005: Eisai Medical Research Inc has sought approval from US Food and Drug Administration (US FDA)  for the anti-epileptic drug (AED) rufinamide.

The company has submitted a new drug application (NDA) to the USFDA seeking approval for two indications for rufinamide, as adjunctive therapy for Lennox-Gastaut syndrome (LGS) in children ages four and over and as adjunctive therapy for partial-onset seizures with and without secondary generalization in adults and adolescents (12 years of age and over), said an official release from Eisai.

Rufinamide is a triazole derivative, a compound structurally distinct from currently approved AEDs. In a multicenter, double-blind, placebo-controlled clinical trial, rufinamide was shown to have clinical benefit in the treatment of seizures associated with LGS, a severe form of epilepsy that develops in early childhood, and was designated as an orphan drug for this indication by the FDA in October 2004.
Based on key findings of two double-blind, placebo-controlled trials, rufinamide will also be filed with the FDA as adjunctive therapy in adults and adolescents, 12 years of age and over, with partial-onset seizures with and without secondary generalization. 

Lennox-Gastaut syndrome is a severe form of epilepsy. Seizures usually begin before four years of age, and children with LGS often suffer from several types of seizures. An estimated 1,400 to 4,500 new cases of LGS are diagnosed each year in the US, and complete recovery, including freedom from seizures and normal development, is very unusual. There is no known cure for the disorder.

Rufinamide also was shown to have clinical benefit as adjunctive therapy in treating adults and adolescents (12 years of age and over) with partial-onset seizures with or without secondary generalization. Partial seizures affect only one area of the brain and are the most common type of seizure experienced by people with epilepsy. 

Eisai acquired exclusive North American and European manufacturing and marketing rights to rufinamide from Novartis Pharma AG in 2004. 

In double-blind studies, the most commonly observed adverse experiences seen in association with rufinamide and at a higher frequency (greater than or equal to 10%) than in placebo-treated patients were headache, dizziness, fatigue, somnolence and nausea.

Eisai Medical Research Inc. is a U.S. pharmaceutical subsidiary of Eisai Co., Ltd. Eisai Medical Research Inc. was established to focus solely on clinical research and to expedite clinical drug development of new chemical entities and of new indications for marketed products.

BY OUR PHARMA CORRESPONDENT

 

RELATED US FDA STORIES

All USFDA news

Dr Reddy's nizatidine generic gets FDA nod 20 Sep, 2005

Abbott’s prostate cancer drug Xinlay unapprovable: US FDA 15 Sep, 2005

US FDA rejects Pfizer's new osteoporosis drug 15 Sep, 2005

Epilepsy drug rufinamide: Eisai seeks US FDA nod 15 Sep, 2005

US FDA approves Takeda’s drug combo for type 2 diabetes

US FDA stalls Roche’ Accutane use in pregnancy

Novo Nordisk’s 24-hour acting insulin Levemir gets US FDA okay

US FDA approves Teva's generic for osteoporosis 

Barr, Teva get fexofenadine approvals from US FDA

Barr gets US FDA okay for clonazepam tabs

FDA tightens restrictions on acne drug

FDA okays acrylic lens for cataract patients 

USFDA’s recall overdrive creates panic among drug users

Roche gets USFDA approval for oral Xeloda

Glaxo applies for FDA approval for Flaurix

US FDA to decide on Plan B morning-after pill by Sept 1

Painkiller patch Duragesic under US FDA probe over patients deaths

Teva gets US FDA nod for mirtazapine anti-depressant 

FDA directs Palladone withdrawal

Zidovudine by Ranbaxy gets US FDA tentative nod

Guidant defibrillator recall: US FDA makes three classifications

AIDS drug stavudine by Aurobindo Pharma gets tentative US FDA

US FDA to source anti-HIV drugs from Indian firms

FDA warning on abortion drug Mifeprex (Mifepristone)

US FDA recalls Baxter’s intravenous pumps

US FDA grants tentative nod to Ranbaxy’s glimepiride

Barr, Teva get fexofenadine approvals from US FDA

Insomnia treatment: ROZEREM approved by FDA

US FDA grants fast track status for GSK’s HIV drug

Halozyme gets FDA nod for bladder cancer therapy

Ranbaxy gets US FDA nod for sumatriptan tabs

US FDA approval for Orchid's ceftriaxone vials

IVAX gets FDA okay for hydrochlorothiazide caps

Ranbaxy gets USFDA nod for glimepiride tabs

US FDA blocks sale of Pharmakon's illegal drugs

   Pharma Home

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us